Show simple item record

dc.contributor.authorLeong, J
dc.contributor.authorWalker, S
dc.contributor.authorSalek, Mir-Saeed Shayegan
dc.date.accessioned2019-12-06T01:08:00Z
dc.date.available2019-12-06T01:08:00Z
dc.date.issued2015-06-11
dc.identifier.citationLeong , J , Walker , S & Salek , M-S S 2015 , ' A practical approach to communicating benefit-risk decisions of medicines to stakeholders. ' , Frontiers in Pharmacology , vol. 6 , 99 , pp. 1-9 . https://doi.org/10.3389/fphar.2015.00099
dc.identifier.issn1663-9812
dc.identifier.otherPURE: 15437066
dc.identifier.otherPURE UUID: b8a25e48-ad53-44b8-967b-dd37afa2bb71
dc.identifier.otherScopus: 84930654274
dc.identifier.urihttp://hdl.handle.net/2299/21960
dc.description© 2015 Leong, Walker and Salek. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
dc.description.abstractPurpose: The importance of a framework for a systematic structured assessment of the benefits and risks has been established, but in addition, it is necessary that the benefit-risk decisions and the processes to derive those decisions are documented and communicated to various stakeholders for accountability. Hence there is now a need to find appropriate tools to enhance communication between regulators and other stakeholders, in a manner that would uphold transparency, consistency and standards. Methods: A retrospective, non-comparative study was conducted to determine the applicability and practicality of a summary template in documenting benefit-risk assessment and communicating benefit-risk balance and conclusions for reviewers to other stakeholders. The benefit-risk (BR) Summary Template and its User Manual was evaluated by 12 reviewers within a regulatory agency in Singapore, the Health Sciences Authority (HSA). Results: The BR Summary Template was found to be adequate in documenting benefits, risks, relevant summaries and conclusions, while the User Manual was useful in guiding the reviewer in completing the template. The BR Summary Template was also considered a useful tool for communicating benefit-risk decisions to a variety of stakeholders. Conclusions: The use of a template may be of value for the communicating benefit-risk assessment of medicines to stakeholders.en
dc.format.extent9
dc.language.isoeng
dc.relation.ispartofFrontiers in Pharmacology
dc.titleA practical approach to communicating benefit-risk decisions of medicines to stakeholders.en
dc.contributor.institutionDepartment of Pharmacy, Pharmacology and Postgraduate Medicine
dc.contributor.institutionPublic Health and Patient Safety Unit
dc.contributor.institutionCentre for Health Services and Clinical Research
dc.contributor.institutionSchool of Life and Medical Sciences
dc.description.statusPeer reviewed
rioxxterms.versionVoR
rioxxterms.versionofrecordhttps://doi.org/10.3389/fphar.2015.00099
rioxxterms.typeJournal Article/Review
herts.preservation.rarelyaccessedtrue


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record